

# Journal Pre-proof



Pretomanid for tuberculosis treatment: An update for clinical purposes

Sara Occhineri, Tommaso Matucci, Laura Rindi, Giusy Tiseo, Marco Falcone, Niccolò Riccardi, Giorgio Besozzi

PII: S2590-2571(22)00048-7

DOI: <https://doi.org/10.1016/j.crphar.2022.100128>

Reference: CRPHAR 100128

To appear in: *Current Research in Pharmacology and Drug Discovery*

Received Date: 20 May 2022

Revised Date: 16 August 2022

Accepted Date: 3 September 2022

Please cite this article as: Occhineri, S., Matucci, T., Rindi, L., Tiseo, G., Falcone, M., Riccardi, Niccolò., Besozzi, G., Pretomanid for tuberculosis treatment: An update for clinical purposes, *Current Research in Pharmacology and Drug Discovery* (2022), doi: <https://doi.org/10.1016/j.crphar.2022.100128>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier B.V.

**CRediT author statement**

**Sara Occhineri:** Investigation, Data Curation, Writing - Original Draft, Writing - Review & Editing; **Tommaso Matucci:** Investigation, Data Curation, Writing - Original Draft, Writing - Review & Editing; **Laura Rindi:** Validation, Supervision; **Giusy Tiseo:** Validation, Supervision; **Marco Falcone:** Validation, Supervision; **Niccolò Riccardi:** Conceptualization, Methodology, Investigation, Data Curation, Writing - Original Draft, Writing - Review & Editing, Validation, Supervision, Project administration; **Giorgio Besozzi:** Conceptualization, Validation, Supervision;

## Pretomanid for tuberculosis treatment: an update for clinical purposes

Pretomanid (PA), a recently introduced antimycobacterial drug derived from nitroimidazole with both solid bactericidal and bacteriostatic effect, and with an excellent effectiveness and tolerability profile, is in the spotlight.



The World Health Organization (WHO) determined to include PA in its guidelines for the treatment of rifampicin-resistant (RR), multi drug resistant (MDR) and pre-extensively drug resistant TB (pre-XDR-TB) with BDQ, LZD and Moxifloxacin (MFX) in a 6-month regimen.



In the future PA may also represent a treatment option for drug-susceptible TB (DS-TB), latent TB infection (LTBI) and non tuberculous mycobacteria (NTM). This narrative review aims to examine current implementation options and future possibilities for PA in the never-ending fight against TB.



**Title:** Pretomanid for tuberculosis treatment: an update for clinical purposes

**Running title:** Pretomanid for TB treatment

**Authors and affiliations:** Sara Occhineri<sup>1,2</sup>, Tommaso Matucci<sup>1,2</sup>, Laura Rindi<sup>3</sup>, Giusy Tiseo<sup>1</sup>, Marco Falcone<sup>1</sup>, Niccolò Riccardi<sup>1,4</sup>, Giorgio Besozzi<sup>4</sup>,

1. Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

2. Università degli studi di Firenze

3. Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

4. StopTB Italia Onlus, Milan, Italy

**Corresponding author:** Niccolò Riccardi, MD. E-mail: niccolo.riccardi@yahoo.it

E-mail addresses: TM [tommaso.matucci@unifi.it](mailto:tommaso.matucci@unifi.it); SO [sara.occhineri@unifi.it](mailto:sara.occhineri@unifi.it); LR [laura.rindi@unipi.it](mailto:laura.rindi@unipi.it); GT [tiseogiusy@gmail.com](mailto:tiseogiusy@gmail.com); MF [marco.falcone@unipi.it](mailto:marco.falcone@unipi.it); NR [niccolo.riccardi@yahoo.it](mailto:niccolo.riccardi@yahoo.it); GB [besozzig@gmail.com](mailto:besozzig@gmail.com)

**Keywords:** Pretomanid, Tuberculosis; Mycobacterium tuberculosis; DR-TB; preXDR-TB; XDR-TB.

**Conflict of interests:** The Authors declare no conflict of interests.

**Funding:** None.

The manuscript has been spell checked and grammar checked

**Authors' contributions:** NR and GB conceived the manuscript; TM, SO, and NR collected and reviewed the data; TM, SO, and NR drafted the manuscript; NR, GT, MF, LR, and GB reviewed the manuscript; all Authors approved the final draft of the manuscript.

## Highlights

- Drug-susceptible and drug-resistant tuberculosis (DS and DR-TB) remain one of the leading causes of deaths from a single infectious disease.
- New, more effective, shorter, all-oral, and safer anti-DR-TB regimens are desperately needed to increase treatment success.
- Pretomanid (PA) is an oral bicyclic nitroimidazooxazine anti-mycobacterial drug active on both replicating and non-replicating mycobacteria.
- PA, in combination with bedaquiline (BDQ) and linezolid (LZD) and/or other drugs, holds the potential to be a game changer for the treatment of DR-TB.
- More studies are needed to define the potential role of PA for shorter and more effective treatment for DS-TB, latent tuberculosis infection (LTBI) and non-tuberculous mycobacteria (NTM).

## Abstract

Coronavirus disease (COVID-19) pandemic determined a 10 years-set back in tuberculosis (TB) control programs. Recent advances in available therapies may help recover the time lost. While Linezolid (LZD) and Bedaquiline (BDQ), previously Group D second line drugs (SLDs) for TB, have been relocated to Group A, other drugs are currently being studied in regimens for drug resistant TB (DR-TB). Among these, Pretomanid (PA), a recently introduced antimycobacterial drug derived from nitroimidazole with both solid bactericidal and bacteriostatic effect, and with an excellent effectiveness and tolerability profile, is in the spotlight. Following promising data obtained from recently published and ongoing randomized controlled trials (RCTs), the World Health Organization (WHO) determined to include PA in its guidelines for the treatment of rifampicin-resistant (RR), multi drug resistant (MDR) and pre-extensively drug resistant TB (pre-XDR-TB) with BDQ, LZD and Moxifloxacin (MFX) in a 6-month regimen. Although further studies on the subject are needed, PA may also represent a treatment option for drug-susceptible TB (DS-TB), latent TB infection (LTBI) and non tuberculous mycobacteria (NTM). This narrative review aims to examine current implementation options and future possibilities for PA in the never-ending fight against TB.

## Introduction

Coronavirus disease (COVID-19) pandemic heavily impacted on the diagnosis and management of tuberculosis (TB) with an estimated global decrease of TB case detection of 18%, and the first increase year-over-year of TB-related deaths since 2005 reported in 2021 (Dheda et al., 2022). Moreover, the economical effects of the COVID-19 pandemic are expected to increase the catastrophic costs for TB treatment in high-burden, limited resources settings (Dheda et al., 2022). If immediate action is not undertaken a 10-years delay in TB control programs has been estimated (Dheda et al., 2022).

TB represents a global health crisis being one of the first causes of death from a single infectious pathogen worldwide; moreover the spread of drug resistant strains (DR-TB) is fueling the TB pandemic (World Health Organization, 2021).

These strains are defined as follows: rifampicin-resistant TB (RR-TB), multi-drug resistant TB (MDR-TB) with resistances to rifampicin (R) and isoniazid (H), pre-extensively drug resistant TB (pre-XDR-TB) with resistances to R, H and a fluoroquinolone (FLQ) among levofloxacin (LFX) or moxifloxacin

(MFX), and extensively drug resistant TB (XDR-TB) with resistances to R, H, LFX or MFX and either bedaquiline (BDQ) or linezolid (LZD) (Li M et al., 2021).

First-line treatment for drug-susceptible pulmonary tuberculosis (DS-TB) requires four drugs administered for six months, with a reported success rate of 86%, while treatment of DR-TB requires longer, more expensive regimens hampered by a greater pill burden (Gotham et al., 2017).

In 2017, the European Center for Disease Prevention and Control (ECDC) reported a success rate of 58.7% for RR/MDR-TB cases and only 43% for XDR-TB at 24 months of follow-up after treatment completion (European center for disease prevention and control, 2017).

Hence the need for shorter, more effective, fully oral regimens with a lighter pill burden in order to increase treatment adherence and ultimately treatment success (van de berg et al, 2021).

Pretomanid (PA), previously known as PA-824, is a new antimycobacterial oral drug approved in 2019 by the US Food and Drug Administration (FDA) (FDA Drug Approval Package, 2019).

Currently, the use of PA is approved in the BDQ-PA-LZD-MFX (BPALM) and BDQ-PA-LZD (BPAL) combined regimens to treat patients at least 14 years old with pulmonary RR, MDR or pre-XDR-TB (World Health Organization, 2022; Lyons, 2021).

In this narrative review, we give an overview of the current use and future perspective of PA for clinical practice.

## Methods

We performed a MEDLINE/PubMed search on May 1st 2022. The search string was as follows: ((PRETOMANID) AND (PA-824)) OR (PA-824). According to PRISMA 2020 flow diagram (Page et al., 2020), of the total 338 papers identified (334 from MEDLINE/PubMed and 4 from clinicaltrials.gov), as shown in Figure 1, 9 were excluded by language screening (language other than English), 145 were excluded by title screening (not pertinent to our narrative review), and 99 were excluded by abstract screening. The remaining 85 papers were screened by full text and discussed by the Authors, who jointly made the final decision about which papers to consider for inclusion. The pertinent references of the selected 85 papers were evaluated and, if considered relevant, eventually included in the manuscript (Figure 1).

Data of ongoing PA clinical trials were retrieved from clinicaltrials.gov/.

Moreover, we attached in supplementary files (Table S1) the full list of papers included in this review.

This narrative review was ultimately organized in the following major chapters: i) PA chemical structure; ii) pharmacokinetics, pharmacodynamics and patent of PA; iii) trial; iv) adverse effects, drug interactions and PA administration in special populations; vi) drug resistance; vii) related cost; viii) future perspective.

### 1) *Chemical Structure*

PA is an oral bicyclic nitroimidazooxazine anti-mycobacterial drug which includes the nitroimidazole pyran A/B ring, an ether link and an hydrophobic side chain. The chemical name is (6S)-2-Nitro-6- {[4-(trifluoromethoxy)phenyl]methoxy} -6,7-dihydro- 5H-imidazo[2,1-b][1,3]oxazine (Figure 2). The molecular formula is C<sub>14</sub>H<sub>12</sub>F<sub>3</sub>N<sub>3</sub>O<sub>5</sub>, and the molecular weight is 359.26 umu. (FDA Drug Approval Package, 2019; Cherian et al., 2011; Pstragowski et al., 2017).

### 2) 2.1 *Pharmacokinetics*

PA needs phase I and II biotransformation by several metabolic pathways. The elimination half-time is estimated at 16 to 20 hours. The mean Tmax is 4-5 hours and the steady state is achieved in 5-6 days. The drug diffuses into the body with a Vd/F of 92-180 L and is modestly bound by albumin (86.3-86.5%). A single daily dose posology is possible due to the good tissue absorption and to the long half-life of this drug. PA crosses the blood-brain barrier due to its lipophilic nature (Bahuguna et al., 2020; Ginsberg et al., 2009; Wang et al., 2015; Stancil et al., 2021; Diacon et al., 2012).

The introduction of the drug with food, especially a high-fat and high-calorie meal, enhances the solubility of the tablets and the gastrointestinal absorption of PA (Winter et al., 2013).

PA is metabolized by cytochrome CYP3A for about 20% of its intake (Pstragowski et al., 2017; Mitnick et al., 2009) and about 53% of the drug's dose is excreted in urine and 38% in feces (Wang et al., 2015).

### 2.2 *Pharmacodynamics*

PA is a prodrug and needs activation by *Mycobacterium tuberculosis* (Mtb) deazaflavin dependent-nitroreductase (ddn) which transforms PA into three primary active metabolites. The drug is clinically

active against replicating and non-replicating bacilli through two main mechanisms of action (Pstragowski et al., 2017; Singh et al., 2008; Malo et al., 2021): 1) in aerobic conditions PA inhibits protein and lipid synthesis, which are essential components of the MTb cell, by a dose-dependent ability to decrease the availability of keto mycolic acids by an inadequate oxidative transformation of precursor hydroxymycolates; 2) in anaerobic state, PA generates des-nitro metabolites and the release of nitric oxide (NO). NO inhibits cytochrome c oxidase that leads to a significant reduction of the ATP concentration in cells (Li et al., 2021; Stancil et al., 2021; Villemagne et al., 2012; D'Ambrosio et al., 2015). This activity under anaerobic condition explains PA efficacy on non-replicating mycobacteria (Stancil et al., 2021; Singh et al., 2008; Manjunatha et al., 2009) comparable to R and LZD efficacy on inhibiting the growth of dormant phenotype Mtb (Diacon et al., 2012; Ahmad et al., 2011; Wong et al., 2013; Fu et al., 2009). In vitro, the compound minimum inhibitory concentration (MIC) was estimated in between 0.015 and 0.25 µg/ml for drug-susceptible Mtb and among 0.03 and 0.53 µg/ml for drug-resistant strains (Pstragowski et al., 2017; Ginsberg et al., 2009). In animal studies, PA showed a time dependent activity during the intensive phase of treatment as well as in the continuation period and a CFU count reduction by 0.1 log<sub>10</sub> units/day over 24 days. The lowest bactericidal dose was 100 mg/kg/day and the minimal effective dose was 12.5 mg/kg/day (Mitnick et al., 2009; Conradie et al., 202; Tyagi et al., 2005). In a human comparative study, early bactericidal activity (EBA), defined as a decrease in log(10) colony forming units (CFU) of MTb per 1 ml of sputum after 14 days of treatment, no difference of response was found between PA at a dosage of 200 mg and 1200 mg establishing 200mg as the minimum effective dosage for pulmonary TB (PTB) (Ahmad et al., 2011).

### *2.3 Patent*

The patent for PA as an anti-mycobacterial agent was released on the 28th of January 2021 with International Publication Number: WO2021/016012A1. Patent description is available at <https://patents.google.com/patent/WO2021016012A1/en>.

### *3) Trials*

The newly released World Health Organization (WHO) guidelines, which included PA in regimens for the treatment of RR-TB, MDR-TB and pre-XDR-TB, were based on the following trials (World Health Organization, 2022).

### **3.1 NC001, NC002, STAND (PaMZ)**

Between 2012 and 2014, 2 phase II trials (NC001 and NC002) confirmed the excellent EBA of PA combined with MFX and pyrazinamide (Z) emerged in preclinical studies (Diacon et al., 2012; Dawson et al., 2015). This regimen was found to be non-inferior to the standard of care, with the eradication of 99% of Mtb after 2 and 8 weeks of treatment, even for MDR-TB cases. Notably, NCOO2 was the first trial to study a regimen both for the treatment of DS-TB and MDR-TB and at the same time to investigate potential interaction with antiretroviral drugs to treat patients with Human Immunodeficiency Virus (HIV) coinfection. These results paved the way for the development of a partially randomized, open-label, non-inferiority Phase 3 clinical trial (STAND-Shortening Treatments by Advancing Novel Drugs) studying the same regimen on 234 adults with DS-TB or RR-TB randomized to either 200 mg PA, 400 mg MFX and 1500 mg Z daily for 6 months (6Pa 200MZ) or 4 months (4Pa 200MZ); 100mg PA for 4 months in the same combination daily (4Pa 100MZ) versus the standard of care (H, R, Z, E daily for 8 weeks, followed by H, R daily for 18 weeks: 2HRZE/4HR). However, 8 months in the trial, the recruitment was paused after three hepatotoxicity associated deaths in the experimental arm. Further examination did not find correlation with drug induced liver injury (DILI) and the trial resumed. Final data showed higher rates of negative outcomes (treatment failure, relapse, adverse events) than the standard of care but, due to the small sample size, the trial was considered underpowered and results were deemed inconclusive (Tweed et al., 2021).

### **3.2 Simplici-TB trial (BPaMZ)**

Following promising preclinical data on improved bactericidal activity, prevention of BDQ resistance and diminished time for relapse-prevention in drug-susceptible isolates with the addition of PA to BDQ-containing regimens several trials were commenced (Xu et al., 2019).

Simplici-TB, an open-label, partially randomized trial, is evaluating the efficacy, tolerability, and safety of BPaMZ regimen for the treatment of DS-TB with BDQ 200 mg daily for 8 weeks then 100 mg daily

for 9 weeks, together with PA 200 mg + MFX 400 mg + Z 1500 mg daily for 17 weeks (total treatment duration 4 months) versus the standard of care (2HRZE+4HR), and for DR-TB with BDQ 200 mg daily for 8 weeks then 100 mg daily for 18 weeks, together with PA 200 mg + MFX 400 mg + Z 1500 mg daily for 26 weeks (total treatment duration 6 months). This trial is currently ongoing, the estimated completion date was February 25, 2022, results were not available at the time of this review (<https://clinicaltrials.gov/ct2/show/NCT03338621>).

### *3.3 Nix-TB (BPaL)*

In 2015 NIX-TB, an open-label, single arm phase III trial, for the study of a regimen including BDQ, LZD and PA for the treatment of XDR-TB and treatment intolerant/non-responsive-TB in South African patients as young as 14 with or without HIV-coinfection (with a CD4+ cell count of 50 or above) was initiated. 71 patients with XDR-TB and 38 patients with MDR-TB were included in this study and orally administered BDQ 400 mg for 2 weeks followed by 200mg thrice-weekly for 24 weeks, PA 200 mg daily and either LZD 600 mg twice daily or LZD 1200 mg once daily for 26 weeks, or 39 weeks for those culture-positives at week 16. A favourable outcome was reported in 89% of XDR-TB, 92% for MDR-TB for a compound positive outcome of 90%. Notably, culture-conversion was obtained in 100% cases in 4 months, while 65% of patients were culture-negative by week 8. Seven total deaths were reported, 6 during the course of treatment,<sup>1</sup> after relapse of disease. Unfortunately, 81% of patients reported peripheral neuropathy and half of the patients were diagnosed with haematological disturbances, common side effects of LZD, highlighting the need for LZD better dose-finding (van de berg et al., 2021; Conradie et al., 2020; Nedelman et al., 2020; Silva et al., 2018; Oelofse et al., 2021).

### *3.4 ZeNIX*

In 2017, ZeNIX trial (phase 3 partially-blinded, randomized trial) followed its predecessor's path to resolve the issue of LZD toxicity, with either a halved duration of therapy or daily dosage of LZD, and to assess effectiveness of such reduced dosage and posology. Preliminary results, presented at the International AIDS Society (IAS) Conference in July 2021, showed that while effectiveness was preserved, as favourable outcomes were reported in 93.2% of patients on 1200 mg of daily LZD for 26 weeks, in 88.9% of patients on 1200 mg of LZD for 9 weeks, in 90.9% of patients on 600 mg of LZD for

26 weeks, in 84.1% of patients on 600 mg of LZD for 9 weeks fewer adverse events were reported. Further analysis of raw data is pending (<https://theprogramme.ias2021.org/Abstract/Abstract/2405>)

### *3.5 TB Practecal*

PA implementation in regimens for MDR-TB is being studied in another multi-centre, open label, multi-arm, randomized, controlled, phase II-III trial named TB PRACTECAL sponsored by *Medecins sans frontières* (MSF). Patients have been randomized in one of three experimental arms, each studying a different combination regimen of BDQ, PA, LZD and MFX or clofazimine (CFZ) with a total duration of 24 weeks. This trial's estimated date of completion is December 2022, no results were available at the time of this review (<https://clinicaltrials.gov/ct2/show/study/NCT02589782> ).

#### *4) Adverse effects*

Real-life data are lacking but most commonly adverse effects related to PA administration reported in trials were: gastrointestinal (GI) symptoms (28,4%), hepatic disorders (25,5%) with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevation (19,2%), skin or subcutaneous tissue disorders (16,6%), headache (11,0%) as shown in Figure 3 (Nedelman et al., 2020).

QTc prolongation was not reported in studies evaluating adverse events during PA monotherapy and is not to be expected at labelled dosing. However, further studies are needed on this matter given the concomitant administration of drugs with demonstrated effect on QTc length (CFZ, BDQ, LFX, MFX), periodic monitoring of QTc with electrocardiogram (ECG) is recommended (Li et al., 2021).

Reversible increases of serum creatinine levels have been consistently reported in literature (Diacon et al., 2010; Olaru et al., 2015). Quite curiously these alterations are considered unreflective of renal function and probably due to selective inhibition of creatinine tubular secretion as a cosmetic side effect (Li et al., 2021; Ginsberg et al., 2009; Diacon et al., 2010; Olaru et al., 2015; Ginsberg et al., 2009).

Transient liver enzyme elevation was also commonly reported in preclinical studies and confirmed in patients receiving PA-containing regimens (LiverTox, 2019; Gils et al., 2022).

While testicular toxicity was noted in male rats administered PA, no effect on male human fertility was reported and sex hormone levels were consistently in range among male trial participants (World Health Organization, 2022; Black et al., 2021). An ongoing trial will further assess the effect of PA on male fertility (<https://clinicaltrials.gov/ct2/show/NCT04179500>)

#### *4.1 Drug-drug Interactions (DDIs)*

The simultaneous intake of some drugs decreases plasma concentration of PA. For example, the area under the curve (AUC) reduction in PA concentration is 66% when coadministered with R, 35% when coadministered with efavirenz and 17% when coadministered with ritonavir (Salinger et al., 2019; Gopalan et al., 2016).

The effect of ritonavir on PA concentration is not clinically significant, therefore these drugs can be administered together in case of necessity (Ignatius et al., 2019). Instead, efavirenz causes the induction of CYP3A which contributes for an estimated 20% to PA metabolism (Dooley et al., 2014). In patients on antiretroviral treatment (ART) the association of PA and efavirenz should be avoided because of the significant reduction in PA exposure caused by efavirenz (Dooley et al., 2014). Darunavir increases PA half-life and reduces its AUC and Cmax (Wang et al., 2018). By contrast PA does not affect the exposure of efavirenz or protease inhibitors like lopinavir or darunavir (Dooley et al., 2014). Initial concerns of a potential interaction between R and PA causing a decrease of AUC in PA concentration (Salinger et al., 2019) were dissipated after an interim analysis determined unlikely an impairment of efficacy if PA was administered with food (Ignatius et al., 2021). Even though H inhibits CYP3A enzymes, there is no evidence of a significant effect on PA kinetics (Ignatius et al., 2021). Conflicting data on an antagonistic effect of PA on the bactericidal activity of BDQ have been reported in literature (Muliaditan et al., 2021). In preclinical studies comparing different combinations of antitubercular drugs, PA added to BDQ and Z containing regimens did not increase EBA but showed reduced rates of relapse (Stancil et al., 2021).

PA does not enhance or inhibit CYP3A activity (Wang et al., 2018). No effects were found on midazolam plasma concentration in patients on treatment with PA (Winter et al., 2013). In vitro studies showed that PA inhibits the OAT3 drug transporter thus leading to an increased risk of adverse events related to the

drugs substrate of this transporter. For instance, methotrexate, an OAT3 substrate, may need dosage adjustment when coadministered with PA (Tyagi et al., 2005).

PA does not alter the activity of cell-wall transporters such as breast cancer resistance protein (BCRP), bile salt export pump (BSEP), multidrug and toxin extrusion 1 and 2 (MATE1, MATE2), organic anion transporter 1 and B1 (OAT1, OAT1B1), organic anion transporting polypeptide 1B3 (OATP1B3), organic cation transporter 1 and 2 (OCT1, OCT2) or p-glycoprotein (P-gp) (FDA Drug Approval Package, 2019).

#### *4.2 Special populations*

No differences based on sex, body weight, race, PTB severity or HIV status has shown to modify PA pharmacokinetics (FDA Drug Approval Package, 2019).

#### *4.3 Pregnancy and breast-feeding*

In animal studies, maternal “no observed adverse effect level” (NOAEL) defined as the greater drug concentration at which no adverse effect is observed, was 10 mg/kg (rat model); embryo-fetal NOAEL was 30-60 mg/kg (rat-rabbit model) [14 Stancil]. A higher concentration of PA was found in milk (1.6 µg/mL) compared to plasma (1.1 µg/mL) (Stancil et al., 2021). To date, no data on PA administration during lactation in humans are available; other drugs should be considered in such circumstances. However, if PA is essential for the mother's treatment and cannot be substituted, both breastfeeding and PA administration should be continued (FDA Drug Approval Package, 2019; Stancil et al., 2021, Drugs and Lactation Database, 2020).

#### *4.4 Children*

Currently there is no data on PA effect and pharmacokinetic in children even though a prototype dispersible pediatric formulation is under evaluation (Garcia-Prats et al., 2006).

#### *4.5 TB-HIV coinfection*

PA, in the BPaL regimen, has shown to be safe and effective in HIV-positive people on ART as well as in HIV-negative people. We recommend that careful assessment of ART, with a switch to antiretroviral treatment without potential DDIs with PA, should be carried out to avoid PA lack of efficacy (Mulder et al., 2022).

### 5) Resistance to PA

Single nucleotide polymorphism (SNPs) mutations, an insertion or a deletion in genes target of the drug or enzymes involved in the drug metabolism can be responsible for PA resistance [56]. Five genes causing 83% of mutations are considered accountable for cross drug resistance to PA and Delamanid (DLM): ddn (29%), fgd1 (7%), fbiA (19%), fbiB (2%), fbiC (26%) (Stancil et al., 2021; Gómez-González et al., 2021). fbiA, fbiB, fbiC, and fbiD are implicated in the biosynthesis of F420, a two-electron transfer cofactor involved in redox reactions and methane pathway (Stancil et al., 2021).

The bacterial ddn encodes for a 151 amino acids F420-dependent nitroreductase that is essential for the activation of the prodrug. A loss of function mutation in fbiD (Rv2983) results in ddn inability to mediate the NAP reduction (Stancil et al., 2021). Ddn mutations can occur spontaneously, frequently (within a range of 10<sup>-5</sup> / 10<sup>-7</sup>), thus rapidly leading to the inactivation of the nitroreductase. Surveillance for ddn polymorphisms should be always conducted (Lee et al., 2020; Kadura et al., 2020) and PA should always be administered in combined regimens in order to prevent the onset of resistances (Stancil et al., 2021; Haver et al., 2015). However, at the moment no standardized rapid method for the detection of PA-resistance is available, with whole genome sequencing as the sole test capable of identification which is not always readily available (Rifat et al., 2020). Furthermore, Rv2983 mutants showed phenotypic sensitivity to the use of malachite green as a selective decontaminant for common solid-media culture, such as Lowenstein-Jensen, possibly hampering the isolation of PA-resistant strains (Rifat et al., 2020).

### 6) Cost analysis of PA

The economic aspect of PA is as relevant as are its chemical properties and clinical applications. DR-TB treatment is extremely expensive, moreover out-of-pocket fees and loss of productivity often represent a catastrophic cost for patients (Mulder et al., 2022) thus affecting adherence to therapy and ultimately treatment outcomes. Ongoing trials in high-burden RR/MDR-TB and XDR-TB settings are showing that BPaL regimen can be two-to-five times cheaper than conventional treatment (Mulder et al., 2022; Gomez et al., 2021). The reduced cost of BPaL derives from a decreased procurement price established by the Global Drug Facility (GDF), from a shorter therapy, from a reduction of the total

number of drugs involved, but also from a reduced use of health services such as outpatient consultations for directly-observed-therapy (DOT), home visits and safety monitoring blood tests (Mulder et al., 2022). The estimated prices of drugs used in XDR-TB treatment were USD \$8-\$17/month for BDQ, \$5-\$16/month for DLM, \$11-\$34/month for PA, \$4-\$9/month for LZD (Mulder et al., 2022). The cost of PA-containing three-drug regimens was expected to be \$53-\$276 while for DLM based four drug regimens (DLM, LZD, BDQ, CFZ, high-dose H - or ethionamide, either with or without Z) is \$238-\$507 (in the current Global Drug Facility list price, a PA treatment is estimated to cost US\$ 364) (Gomez et al., 2021).

#### *7) Future challenges for implementation of PA in the treatment of TB*

Current indications of PA use are shown in Figure 4. The use of PA in settings other than the treatment of DR-TB has been evaluated. As previously said, in STAND and Simplici-TB trial, PA was tested against Mtb drug-susceptible strains (Tweed et al., 2021; Xu et al., 2019). In STAND trial, PA-containing regimens administered to DS-TB have shown a superior bactericidal effect compared to standard of care (McKenna et al., 2019) even though higher rates of adverse events were reported, possibly due to the concomitant administration of companion drugs with known high rates of adverse events (Riccardi et al., 2020). In a Phase II dose ranging randomized trial, a dose of 100 mg to 200 mg PA daily appeared safe and effective against DS-TB (Tweed et al., 2019). BloadPaZ and B200PaZ are encouraging regimens for the treatment of patients with DS-TB. PA based regimens could then decrease treatment duration and pill burden for DS-TB (Tweed et al. 2019). Another motive to implement alternative regimens for DS-TB is the poor performance of the standard of care (2HRZE4HR) when the relatively frequent H-monoresistance is present (Tweed et al. 2019).

Furthermore, given its dual activity on both replicating and non-replicating MTb, PA represents an interesting option for new regimens for latent tuberculosis infection (LTBI) of both DS and DR-TB. Studies in animal models showed limited activity of PA monotherapy in LTBI while further data is needed to assess its usage in combination therapy in order to reduce treatment length and side effects (Dutta et al., 2014; Somasundaram et al., 2013)

Given the expected use on a large scale of PA, the development of readily available methods for drug-resistance detection through molecular and phenotypic tests is urgently needed (Rifat et al., 2020).

PA could turn into an ally in the challenging treatment of non tuberculous mycobacteria (NTM) species. However, *M. avium*, *M. intracellulare*, *M. abscessus* and *M. fortuitum* are innately resistant to PA. No effectiveness was found against *M. leprae*. The activity against *M. ulcerans* ( $\leq 4$  to  $\geq 16$   $\mu\text{g/mL}$ ) appears to be lower [14 Stancil]. It is unclear if the drug is active against *M. kansasii* (Stancil et al., 2021). The different resistant pattern of NTM against PA may lie in the presence of alternative forms of ddn sequences, essentials for the activation of the prodrug (Zhang et al., 2020).

Alternative drug formulations to oral PA tablets were also tested, such as a dry powder formulation for aerosol inhalation with reportedly similar pharmacokinetics behaviors (Sung et al., 2009). Sung et al. showed higher stability of this formulation and a better pharmacokinetic profile than oral or intravenous administration. Topical administration may permit PA dosage reduction and further decrease treatment duration and systemic side effects (Villemagne et al., 2012; Sung et al., 2009).

### Conclusions

The implementation of recently approved combinations of antitubercular drugs for a shorter, safer and overall more effective treatment for DR-TB may contribute to reduce the estimated 10-years delay in TB control programs due to the COVID-19 pandemic (Dheda et al., 2022), although the precise effect of the current Ukrainian crisis, which is expected to increase the percentage of patients living with TB without proper care (Sotgiu et al., 2022), has yet to be assessed.

In this landscape, attempts to reduce treatment duration also for DS-TB and LTBI are fundamental. Given its optimal safety and effectiveness profile, PA, among other drugs, holds the potential to be one of the main actors for future positive developments in TB control and eradication.

### Bibliography

Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grossset JH, Nuermberger EL. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. *Antimicrob Agents Chemother.* 2011 Jan;55(1):239-45. doi: 10.1128/AAC.00849-10.

Bahuguna A, Rawat DS. An overview of new antitubercular drugs, drug candidates, and their targets. *Med Res Rev.* 2020 Jan;40(1):263-292. doi: 10.1002/med.21602.

Black TA, Buchwald UK. The pipeline of new molecules and regimens against drug-resistant tuberculosis. *J Clin Tuberc Other Mycobact Dis.* 2021;25:100285. Published 2021 Nov 5. doi:10.1016/j.jctube.2021.100285

Cherian J, Choi I, Nayyar A, Manjunatha UH, Mukherjee T, Lee YS, Boshoff HI, Singh R, Ha YH, Goodwin M, Lakshminarayana SB, Niyomrattanakit P, Jiricek J, Ravindran S, Dick T, Keller TH, Dartois V, Barry CE 3rd. Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824). *J Med Chem.* 2011 Aug 25;54(16):5639-59. doi: 10.1021/jm1010644. Epub 2011 Jul 26.

Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J, McHugh TD, Wills GH, Bateson A, Hunt R, Van Niekerk C, Li M, Olugbosi M, Spigelman M; Nix-TB Trial Team. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. *N Engl J Med.* 2020 Mar 5;382(10):893-902. doi: 10.1056/NEJMoa1901814.

D'Ambrosio L, Centis R, Sotgiu G, Pontali E, Spanevello A, Migliori GB. New anti-tuberculosis drugs and regimens: 2015 update. *ERJ Open Res.* 2015 May 6;1(1):00010-2015. doi: 10.1183/23120541.00010-2015.

Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in

patients with drug-susceptible or drug-resistant pulmonary tuberculosis. *Lancet.* 2015 May 2;385(9979):1738-1747. doi: 10.1016/S0140-6736(14)62002-X. Epub 2015 Mar 18.

Dheda, K., Perumal, T., Moultrie, H., Perumal, R., Esmail, A., Scott, A. J., Udwadia, Z., Chang, K. C., Peter, J., Pooran, A., von Delft, A., von Delft, D., Martinson, N., Loveday, M., Charalambous, S., Kachingwe, E., Jassat, W., Cohen, C., Tempia, S., Fnelly, K., ... Pai, M. (2022). The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. *The Lancet. Respiratory medicine,* S2213-2600(22)00092-3. Advance online publication. [https://doi.org/10.1016/S2213-2600\(22\)00092-3](https://doi.org/10.1016/S2213-2600(22)00092-3)

Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, Erondu N, Ginsberg AM, Becker P, Spigelman MK. Phase II dose-ranging trial of the early bactericidal activity of PA-824. *Antimicrob Agents Chemother.* 2012 Jun;56(6):3027-31. doi: 10.1128/AAC.06125-11.

Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, Donald PR, van Niekerk C, Whitney K, Rouse DJ, Laurenzi MW, Ginsberg AM, Spigelman MK. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. *Antimicrob Agents Chemother.* 2010 Aug;54(8):3402-7. doi: 10.1128/AAC.01354-09.

Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. *Lancet.* 2012 Sep 15;380(9846):986-93. doi: 10.1016/S0140-6736(12)61080-0. Epub 2012 Jul 23.

Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW; AIDS Clinical Trials Group A5306 Study Team. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. *Antimicrob Agents Chemother.* 2014 Sep;58(9):5245-52. doi: 10.1128/AAC.03332-14. Epub 2014 Jun 23.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Pretomanid. 2020 Sep 21. Available at <https://www.ncbi.nlm.nih.gov/books/NBK501922/>

Dutta NK, Karakousis PC. PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice. *Int J Antimicrob Agents*. 2014 Dec;44(6):564-6. doi: 10.1016/j.ijantimicag.2014.07.012. Epub 2014 Sep 16.

European center for disease prevention and control (ECDC)

FDA Drug Approval Package: Pretomanid. Revised: 8/2019 Available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2019/212862Orig1s000Lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212862Orig1s000Lbl.pdf).

Fu LM, Tai SC. The Differential Gene Expression Pattern of *Mycobacterium tuberculosis* in Response to Capreomycin and PA-824 versus First-Line TB Drugs Reveals Stress- and PE/PPE-Related Drug Targets. *Int J Microbiol*. 2009;2009:879621. doi: 10.1155/2009/879621.

Garcia-Prats AJ, Svensson EM, Weld ED, Schaaf HS, Hesseling AC. Current status of pharmacokinetic and safety studies of multidrug-resistant tuberculosis treatment in children. *Int J Tuberc Lung Dis*. 2018 May 1;22(5):15-23. doi: 10.5588/ijtld.17.0355.

Gils T, Lynen L, de Jong BC, Van Deun A, Decroo T. Pretomanid for tuberculosis: a systematic review. *Clin Microbiol Infect*. 2022 Jan;28(1):31-42. doi: 10.1016/j.cmi.2021.08.007.

Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects. *Antimicrob Agents Chemother*. 2009 Sep;53(9):3726-33. doi: 10.1128/AAC.00112-09.

Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. *Antimicrob Agents Chemother*. 2009 Sep;53(9):3720-5. doi: 10.1128/AAC.00106-09.

Global tuberculosis report 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IG

Gomez GB, Siapka M, Conradie F, Ndjeka N, Garfin AMC, Lomtadze N, Avaliani Z, Kiria N, Malhotra S, Cook-Scalise S, Juneja S, Everitt D, Spigelman M, Vassall A. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines. *BMJ Open*. 2021 Dec 3;11(12):e051521. doi: 10.1136/bmjopen-2021-051521.

Gómez-González PJ, Perdigao J, Gomes P, Puyen ZM, Santos-Lazaro D, Napier G, Hibberd ML, Viveiros M, Portugal I, Campino S, Phelan JE, Clark TG. Genetic diversity of candidate loci linked to *Mycobacterium* tuberculosis resistance to bedaquiline, delamanid and pretomanid. *Sci Rep*. 2021 Sep 30;11(1):19431. doi: 10.1038/s41598-021-98862-4.

Gopalan N, Chandrasekaran P, Swaminathan S, Tripathy S. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. *AIDS Res Ther*. 2016 Sep 26;13:34. doi: 10.1186/s12981-016-0118-7.

Gotham D, Fortunak J, Pozniak A, Khoo S, Cooke G, Nytko FE 3rd, Hill A. Estimated generic prices for novel treatments for drug-resistant tuberculosis. *J Antimicrob Chemother*. 2017 Apr 1;72(4):1243-1252. doi: 10.1093/jac/dkw522.

Haver HL, Chua A, Ghode P, Lakshminarayana SB, Singhal A, Mathema B, Wintjens R, Bifani P. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of *Mycobacterium* tuberculosis. *Antimicrob Agents Chemother*. 2015 Sep;59(9):5316-23. doi: 10.1128/AAC.00308-15. Epub 2015 Jun 22.

<https://clinicaltrials.gov/ct2/show/NCT03338621>

<https://clinicaltrials.gov/ct2/show/NCT04179500>

<https://clinicaltrials.gov/ct2/show/study/NCT02589782>

<https://theprogramme.ias2021.org/Abstract/Abstract/2405>

Ignatius EH, Abdelwahab MT, Hendricks B, Gupte N, Narunsky K, Wiesner L, Barnes G, Dawson R, Dooley KE, Denti P. Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. *Antimicrob Agents Chemother.* 2021 Jan 20;65(2):e01196-20. doi: 10.1128/AAC.01196-20.

Ignatius EH, Dooley KE. New Drugs for the Treatment of Tuberculosis. *Clin Chest Med.* 2019 Dec;40(4):811-827. doi: 10.1016/j.ccm.2019.08.001.

International Publication with International Publication Number: WO2021/016012A1. Patent description is available at <https://patents.google.com/patent/WO2021016012A1/en>.

Kadura S, King N, Nakhoul M, Zhu H, Theron G, Köser CU, Farhat M. Systematic review of mutations associated with resistance to the new and repurposed *Mycobacterium tuberculosis* drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. *J Antimicrob Chemother.* 2020 Aug 1;75(8):2031-2043. doi: 10.1093/jac/dkaa136.

Lee BM, Harold LK, Almeida DV, Afriat-Jurnou L, Aung HL, Forde BM, Hards K, Pidot SJ, Ahmed FH, Mohamed AE, Taylor MC, West NP, Stinear TP, Greening C, Beatson SA, Nuermberger EL, Cook GM, Jackson CJ. Predicting nitroimidazole antibiotic resistance mutations in *Mycobacterium tuberculosis* with protein engineering. *PLoS Pathog.* 2020 Feb 7;16(2):e1008287. doi: 10.1371/journal.ppat.1008287.

Li M, Saviolakis GA, El-Amin W, Makhene MK, Osborn B, Nedelman J, Yang TJ, Everitt D. Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers. *Clin Pharmacol Drug Dev.* 2021 Jun;10(6):634-646. doi: 10.1002/cpdd.898. Epub 2020 Dec 30.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Pretomanid. 2019 Nov 4.

Lyons MA. Pretomanid dose selection for pulmonary tuberculosis: An application of multi-objective optimization to dosage regimen design. *CPT Pharmacometrics Syst Pharmacol.* 2021 Mar;10(3):211-219. doi: 10.1002/psp4.12591. Epub 2021 Feb 13.

Malo A, Kellermann T, Ignatius EH, Dooley KE, Dawson R, Joubert A, Norman J, Castel S, Wiesner L. A validated liquid chromatography tandem mass spectrometry assay for the analysis of pretomanid in plasma samples from pulmonary tuberculosis patients. *J Pharm Biomed Anal.* 2021 Feb 20;195:113885. doi: 10.1016/j.jpba.2020.113885.

Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: Novel insights from transcriptional profiling. *Commun Integr Biol.* 2009 May;2(3):215-8. doi: 10.4161/cib.2.3.7926.

McKenna L, Furin J. Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative? *Lancet Respir Med.* 2019 Dec;7(12):999-1000. doi: 10.1016/S2213-2600(19)30363-7. Epub 2019 Nov 12.

Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. *Expert Opin Pharmacother.* 2009 Feb;10(3):381-401. doi: 10.1517/14656560802694564.

Mulder C, Rupert S, Setiawan E, Mambetova E, Edo P, Sugiharto J, Useni S, Malhotra S, Cook-Scalise S, Pambudi I, Kadyrov A, Lawanson A, van den Hof S, Gebhard A, Juneja S, Sohn H. Budgetary impact of using BPoL for treating extensively drug-resistant tuberculosis. *BMJ Glob Health.* 2022 Jan;7(1):e007182. doi: 10.1136/bmjgh-2021-007182.

Muliaditan M, Della Pasqua O. Evaluation of pharmacokinetic-pharmacodynamic relationships and selection of drug combinations for tuberculosis. *Br J Clin Pharmacol.* 2021 Jan;87(1):140-151. doi: 10.1111/bcp.14371. Epub 2020 Jun 30.

Nedelman JR, Salinger DH, Subramoney V, Woolson R, Wade K, Li M, Everitt D, Mendel CM, Spigelman M. An Exposure-Response Perspective on the Clinical Dose of Pretomanid. *Antimicrob Agents Chemother.* 2020 Dec 16;65(1):e01121-20. doi: 10.1128/AAC.01121-20.

Oelofse S, Esmail A, Diacon AH, Conradie F, Olayanju O, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Wills GH, Olugbosi M, Del Parigi A, Sun E, Calatroni A, Spigelman M, Dheda K. Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts. *Int J Tuberc Lung Dis.* 2021 Jun 1;25(6):453-460. doi: 10.5588/ijtld.21.0035.

Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J, Yew WW, Lange C, Chang KC. Novel drugs against tuberculosis: a clinician's perspective. *Eur Respir J.* 2015 Apr;45(4):1119-31. doi: 10.1183/09031936.00162314.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

Pstragowski M, Zbrzezna M, Bujalska-Zadrożny M. ADVANCES IN PHARMACOTHERAPY OF TUBERCULOSIS. *Acta Pol Pharm.* 2017 Jan;74(1):3-11.

Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2022 (WHO/UCN/TB/2022.2). Licence: CC BY-NC-SA 3.0 IGO.

Riccardi N, Canetti D, Rodari P, Besozzi G, Saderi L, Dettori M, Codicosa LR, Sotgiu G. Tuberculosis and pharmacological interactions: A narrative review. *Curr Res Pharmacol Drug Discov.* 2020 Dec 15;2:100007. doi: 10.1016/j.crphar.2020.100007.

Rifat D, Li SY, Ioerger T, et al. Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother.* 2020;65(1):e01948-20. Published 2020 Dec 16. doi:10.1128/AAC.01948-20

Salinger DH, Subramoney V, Everitt D, Nedelman JR. Population Pharmacokinetics of the Antituberculosis Agent Pretomanid. *Antimicrob Agents Chemother.* 2019 Sep 23;63(10):e00907-19. doi: 10.1128/AAC.00907-19.

Silva DR, Dalcolmo M, Tiberi S, Arbex MA, Munoz-Torrico M, Duarte R, D'Ambrosio L, Visca D, Rendon A, Gaga M, Zumla A, Migliori GB. New and repurposed drugs to treat multidrug-

and extensively drug-resistant tuberculosis. *J Bras Pneumol.* 2018 Apr;44(2):153-160. doi: 10.1590/s1806-37562017000000436.

Singh R, Manjunatha U, Boshoff HI, Ha YH, Niyomrattanakit P, Ledwidge R, Dowd CS, Lee IY, Kim P, Zhang L, Kang S, Keller TH, Jiricek J, Barry CE 3rd. PA-824 kills nonreplicating *Mycobacterium tuberculosis* by intracellular NO release. *Science.* 2008 Nov 28;322(5906):1392-5. doi: 10.1126/science.1164571.

Somasundaram S, Anand RS, Venkatesan P, Paramasivan CN. Bactericidal activity of PA-824 against *Mycobacterium tuberculosis* under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor. *BMC Microbiol.* 2013 Oct 1;13:218. doi: 10.1186/1471-2180-13-218.

Sotgiu G, Solovic I, Zenner D, Tiberi S, Manika K, Celan C, Chorostowska-Wynimko J, Zumla A, Migliori GB. The war in Ukraine and potential consequences for the TB epidemic in Europe. *Int J Tuberc Lung Dis.* 2022 May 1;26(5):470-471. doi: 10.5588/ijtld.22.0162.

Stancil SL, Mirzayev F, Abdel-Rahman SM. Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date. *Drug Des Devel Ther.* 2021 Jun 28;15:2815-2830. doi: 10.2147/DDDT.S281639.

Sung JC, Garcia-Contreras L, Verberkmoe JL, Peloquin CA, Elbert KJ, Hickey AJ, Edwards DA. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. *Antimicrob Agents Chemother.* 2009 Apr;53(4):1338-43. doi: 10.1128/AAC.01389-08. Epub 2009 Jan 12.

Tweed CD, Dawson R, Burger DA, Conradie A, Crook AM, Mendel CM, Conradie F, Diacon AH, Ntinginya NE, Everitt DE, Haraka F, Li M, van Niekerk CH, Okwera A, Rassool MS, Reither K, Sebe MA, Staples S, Variava E, Spigelman M. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. *Lancet Respir Med.* 2019 Dec;7(12):1048-1058. doi: 10.1016/S2213-2600(19)30366-2. Epub 2019 Nov 12.

Tweed CD, Wills GH, Crook AM, et al. A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB. *Int J Tuberc Lung Dis.* 2021;25(4):305-314. doi:10.5588/ijtld.20.0513

Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W, Grossset J. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. *Antimicrob Agents Chemother.* 2005 Jun;49(6):2289-93. doi: 10.1128/AAC.49.6.2289-2293.2005.

van de Berg SEJ, Pelzer PT, van der Land AJ, Abdurakhmanova E, Ozi AM, Arias M, Cook-Scalise S, Dravniec G, Gebhard A, Juneja S, Handayani R, Kappel D, Kimerling M, Koppelaar I, Malhotra S, Myrzaliev B, Nsa B, Sugiharto J, Engel N, Mulder C, van den Hof S. Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients. *BMC Public Health.* 2021 Jul 16;21(1):1404. doi: 10.1186/s12889-021-11427-y.

Villemagne B, Crauste C, Flipo M, Baulard AR, Déprez B, Willand N. Tuberculosis: the drug development pipeline at a glance. *Eur J Med Chem.* 2012 May;51:1-16. doi: 10.1016/j.ejmech.2012.02.033.

Wang L, Ma Y, Duan H, Yao J, Liang L, Zhang R, Zhou X, Liu X, Wang Q, Zhang S. Pharmacokinetics and tissue distribution study of PA-824 in rats by LC-MS/MS. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2015 Dec 1;1006:194-200. doi: 10.1016/j.jchromb.2015.10.039.

Wang L, Zhao J, Zhang R, Mi L, Shen X, Zhou N, Feng T, Jing J, Liu X, Zhang S. Drug-Drug Interactions Between PA-824 and Darunavir Based on Pharmacokinetics in Rats by LC-MS-MS. *J Chromatogr Sci.* 2018 Apr 1;56(4):327-335. doi: 10.1093/chromsci/bmy002.

Winter H, Egizi E, Erondu N, Ginsberg A, Rouse DJ, Severynse-Stevens D, Pauli E, Everitt D. Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects. *Antimicrob Agents Chemother.* 2013 Aug;57(8):3699-703. doi: 10.1128/AAC.02632-12. Epub 2013 May 20.

Winter H, Ginsberg A, Egizi E, Erondi N, Whitney K, Pauli E, Everitt D. Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects. *Antimicrob Agents Chemother.* 2013 Nov;57(11):5516-20. doi: 10.1128/AAC.00798-13.

Wong EB, Cohen KA, Bishai WR. Rising to the challenge: new therapies for tuberculosis. *Trends Microbiol.* 2013 Sep;21(9):493-501. doi: 10.1016/j.tim.2013.05.002.

Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis. *Antimicrob Agents Chemother.* 2019 Apr 25;63(5):e00021-19. doi: 10.1128/AAC.00021-19.

Zhang F, Li S, Wen S, Zhang T, Shang Y, Huo F, Xue Y, Li L, Pang Y. Comparison of in vitro Susceptibility of Mycobacteria Against PA-824 to Identify Key Residues of Ddn, the Deazoflavin-Dependent Nitroreductase from *Mycobacterium tuberculosis*. *Infect Drug Resist.* 2020 Mar 11;13:815-822. doi: 10.2147/IDR.S240716.




Figure 1. PRISMA flow diagram adapted for our narrative review.




Figure 2. Pretomanid chemical structure.





Figure 3. Most common adverse events reported during PA administration in combination regimens (Nedelman et al., 2020).

(INSERT ATTACHED FILE Fig. 4 for quality pdf.file)

\*For LZD dose finding is currently ongoing and therapeutic drug monitoring may be needed

Figure 4. Therapeutic algorithm for PA-containing regimens.



\*For LZD dose finding is currently ongoing and therapeutic drug monitoring may be needed

Figure 4. Therapeutic algorithm for PA-containing regimens.

Journal Pre-proof

## Highlights

- Drug-sensible and drug-resistant tuberculosis (DS and DR-TB) remain one of the leading causes of deaths from a single infectious disease.
- New, more effective, shorter, all-oral, and safer anti-DR-TB regimens are desperately needed to increase treatment success.
- Pretomanid (PA) is an oral bicyclic nitroimidazooxazine anti-mycobacterial drug active on both replicating and non-replicating mycobacteria.
- PA, in combination with bedaquiline (BDQ) and linezolid (LZD) and/or other drugs, holds the potential to be a game changer for the treatment of DR-TB.
- More studies are needed to define the potential role of PA for shorter and more effective treatment for DS-TB, latent tuberculosis infection (LTBI) and non-tuberculous mycobacteria (NTM).

**Declaration of interests**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: